AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15145035
Drug: Arthroscopy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arthroscopy with sodium hyaluronate infusion
Trial: 8180671
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.02-0.05 IU/kg body wt sc daily)
Trial: 10896637
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone
Trial: 18812659
Drug: valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 80 mg/d
Trial: 16368298
Drug: valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: valsartan 160 mg/d
Trial: 10960199
Drug: Routine O(2)
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine O(2) therapy (control group)
Trial: 8773861
Drug: Midazolam 0.1
RxNorm normalized name: midazolam 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.1 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group MT)
Trial: 8773861
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg.kg‐1 (group P)
Trial: 8773861
Drug: Lidocaine 1.5
RxNorm normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 1.5 mg.kg‐1 and 5 mg.kg‐1 thiopentone (group LT)
Trial: 6499510
Drug: Dantrolene sodium
RxNorm normalized name: Dantrolene Sodium
DrugBank: Dantrolene (DB01219)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dantrolene sodium (average dose 165.4 mg/day)
Trial: 29547962
Drug: Four open-label
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four open-label placebo pills per day
Trial: 19332659
Drug: Physiological sex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological sex steroid replacement (transdermal estradiol and vaginal progesterone)
Trial: 19332659
Drug: Standard sex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard sex steroid replacement (oral ethinylestradiol and norethisterone)
Trial: 15884282
Drug: 200 microg
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 microg oral misoprostol, six hourly for a maximum of four doses
Trial: 9084795
Drug: Control treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatments (ZDV or ZDV/zalcitabine)
Trial: 22513778
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg/day
Trial: 17443465
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B 3 mg/kg per day
Trial: 17443465
Drug: Liposomal amphotericin
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal amphotericin B 10 mg/kg per day
Trial: 30704697
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 600mg twice daily
Trial: 30704697
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) with long-acting inhaled bronchodilator(s) but no ICS
Trial: 27776269
Drug: Counselor-delivered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselor-delivered treatment (Arm 1)
Trial: 23393065
Drug: Dexamethasone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (20 mg orally) with 8 h of isocapnic hypoxia
Trial: 17923015
Drug: Gelatin group
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin group (GEL group)
Trial: 2539403
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg orally three times per day
Trial: 25722382
Drug: Tecemotide (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tecemotide (in concurrent chemoradiotherapy subgroup)
Trial: 25722382
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in concurrent chemoradiotherapy subgroup)
Trial: 23430455
Drug: 6-month lifestyle
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month lifestyle intervention for weight loss (weekly group sessions for 6 months, followed by 12 months of biweekly contacts)
Trial: 22052225
Drug: Levofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (500 mg orally once daily on days 5 to 11)
Trial: 16391577
Drug: 8.4 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.4 mg/day riboflavin (R group)
Trial: 15080016
Drug: Elderberry syrup
RxNorm normalized name: Nature's Way Sambucus Elderberry Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderberry syrup (15 ml, four times a day for 5 days)
Trial: 1546818
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup
Trial: 9522869
Drug: Glucose-based oral
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-based oral rehydration solution (ORS)
Trial: 9076618
Drug: Rice-based oral
RxNorm normalized name: Rice
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice-based oral rehydration solution (ORS)
Trial: 2672871
Drug: Homologous fresh
RxNorm normalized name: Peroxi-Fresh
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homologous fresh frozen plasma (FFP), 2 units (430 +/- 11 ml) given after the end of extracorporeal circulation (ECC)
Trial: 342625
Drug: Bivalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalent influenza A virus vaccines (200 or 400 CCA units of A/New Jersey/8/76 and A/Victoria/3/75)
Trial: 23950585
Drug: Natalizumab 300
RxNorm normalized name: natalizumab 300 MG in 15 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab 300 mg intravenously once monthly (infusion every 4 weeks)
Trial: 19625629
Drug: Palosuran (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palosuran (5 to 2000 mg, oral doses)
Trial: 17445284
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g high molecular weight (HMW) BBG
Trial: 16330295
Drug: Glyburide/Metformin (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/Metformin (1.25 mg/250 mg BID for 6 days)
Trial: 16330295
Drug: Memantine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (20 mg) and Glyburide/Metformin coadministered
Trial: 12167274
Drug: Enfuvirtide (T-20)
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (T-20) 100 mg bid SC injection
Trial: 12167274
Drug: Enfuvirtide (T-20)
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (T-20) 50 mg bid SC injection
Trial: 10203570
Drug: Meal A
RxNorm normalized name: Yardley Oatmeal and Almond Bath Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal A (600 g spinach)
Trial: 7607966
Drug: Conventional fractionation
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fractionation (once daily 1.8‐2.0 Gy)
Trial: 7607966
Drug: Hyperfractionated split‐course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperfractionated split‐course irradiation (twice daily 1.6 Gy)
Trial: 2393075
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg alfentanil (A3)
Trial: 681295
Drug: amoxapine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amoxapine (300 mg)
Trial: 681295
Drug: amitriptyline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amitriptyline (150 mg)
Trial: 31673419
Drug: tofacitinib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib monotherapy
Trial: 20623180
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy (NT)
Trial: 20623180
Drug: Pre-chemotherapy sHER2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-chemotherapy sHER2 levels
Trial: 20623180
Drug: sHER2 cut-off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sHER2 cut-off level of 10 ng/ml
Trial: 17624687
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose diazepam (40 mg)
Trial: 17624687
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose opioid administration (150% normal dose)
Trial: 16625983
Drug: Omeprazole group
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole group (1-week omeprazole 20 mg twice daily)
Trial: 11307252
Drug: Anolyte neutral
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anolyte neutral cathodic (ANC) (300 mg L‐1 of active chlorine)
Trial: 11307252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anolyte ANC and catholyte
Trial: 11307252
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ANC and catholyte
Trial: 9122640
Drug: Reduced osmolarity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced osmolarity oral rehydration salt (ORS) solution (sodium 67, potassium 20, chloride 66, citrate 7, glucose 89 mmol/l, osmolality 249 mOsmol/kg)
Trial: 9122640
Drug: Reduced osmolarity
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced osmolarity oral rehydration salt (ORS) solution
Trial: 24271261
Drug: Synbiotic food
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic food (1 × 10⁷ CFU Lactobacillus sporogenes and 0.04 g inulin HPX/g) consumed two times a day for 9 weeks
Trial: 23394513
Drug: Fexofenadine at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine at fourfold dose
Trial: 18771886
Drug: Endovascular revascularization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular revascularization and best medical treatment (group A)
Trial: 10551919
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg (group-M)
Trial: 8916058
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine premedication
Trial: 8916058
Drug: No morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No morphine
Trial: 21041485
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment in pregnancy (IPTp)
Trial: 15491374
Drug: Bifidobacterium breve
RxNorm normalized name: Bifidobacterium Breve
DrugBank: Bifidobacterium breve (DB16549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifidobacterium breve (B. breve) supplement, 1.6 x 10(8) cells, twice a day, starting 24 hours after birth (Group B)
Trial: 15491374
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Group C), no supplement
Trial: 12575591
Drug: Compound Salvia
RxNorm normalized name: Salvia sclarea seed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Salvia Injection (CSI) added to conventional treatment
Trial: 7887107
Drug: LF+TEA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF+TEA group receiving low dose fentanyl (15 micrograms.kg‐1) + TEA
Trial: 31477164
Drug: Peer education
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer education intervention (up to two groups per puskesmas, led by trained individuals with diabetes, sessions held monthly for 18 months)
Trial: 25792638
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg daily) and bevacizumab (15 mg·kg(‐1) on day 1, every 3 weeks)
Trial: 25792638
Drug: Cisplatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (80 mg·m(‐2) on day 1, every 3 weeks) and gemcitabine (1250 mg·m(‐2) on days 1 and 8, every 3 weeks) and bevacizumab (15 mg·kg(‐1) on day 1, every 3 weeks)
Trial: 19840379
Drug: Sulfasalazine (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (1.5, 3, 4.5, or 6 grams daily)
Trial: 16930141
Drug: Pegfilgrastim (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegfilgrastim (6 mg single dose on day 1 post-transplant)
Trial: 15191542
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of benzophenone-3 (BP-3)
Trial: 15191542
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of octyl-methoxycinnamate (OMC)
Trial: 15191542
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of 3-(4-methyl-benzylidene) camphor (4-MBC)
Trial: 15191542
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of sunscreens (BP-3, OMC, 4-MBC)
Trial: 9443587
Drug: Dopamine precursor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine precursor (L-DOPA) - 4 mg/kg Sinemet
Trial: 31851017
Drug: Histopathological evaluation
RxNorm normalized name: STOMATOLOGICAL PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histopathological evaluation with high-density laser treatment
Trial: 30728003
Drug: ART+C (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART+C (1 mg/kg corticosteroids)
Trial: 8318320
Drug: Bupivacaine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine infusion
Trial: 9850268
Drug: Intraoperative MMC
RxNorm normalized name: MMC
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative MMC (0.2 mg/ml for 3 min) with post-operative 5-FU (5 mg in 0.5 ml of balanced salt solution) and ocular massage (OM)
Trial: 9850268
Drug: Standard trabeculectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard trabeculectomy with post-operative 5-FU (5 mg in 0.5 ml of balanced salt solution) and ocular massage (OM)
Trial: 2664728
Drug: Meclofenomate 100
RxNorm normalized name: meclofenamate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclofenomate 100 mg t.i.d. for 5 days
Trial: 923067
Drug: Tocainide (400-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (400-600 mg loading doses, maintenance doses every 12 hours)
Trial: 923067
Drug: Tocainide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocainide (400 to 1100 mg every 12 hours during cross-over)
Trial: 29315019
Drug: Daily almond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily almond intake (56 g per day for 20 weeks)
Trial: 15327724
Drug: Imitative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imitative treatment
Trial: 9335367
Drug: Heparin-coated cardiopulmonary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated cardiopulmonary bypass system
Trial: 24240061
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise with ultrasound and microcurrent therapy
Trial: 16679823
Drug: Glycerol-based hydration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol-based hydration cream
Trial: 8817007
Drug: Ambulatory blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory blood pressure (ABP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Trial: 8817007
Drug: Conventional blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional blood pressure (CBP) group, lisinopril 10 mg/day, could be adjusted to 10 or 20 mg/day or discontinued after one month based on blood pressure levels.
Trial: 31663816
Drug: Anabolic androgen
RxNorm normalized name: Anabolic androgenic steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anabolic androgen steroids (AS) users
Trial: 631039
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral Ro 10-9359 and local dithranol application
Trial: 31766250
Drug: Low-dose iron
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iron MNP (5.0 mg iron)
Trial: 28947039
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 100 μg (FF)
Trial: 26520227
Drug: Mindfulness Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Therapy for Maladaptive Interpersonal Dependency (MT‐MID)
Trial: 16317312
Drug: Risperidone (4.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4.6 mg/day mean dose)
Trial: 16432076
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) maintenance therapy
Trial: 9313875
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy package including IFN
Trial: 8313405
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg of nifedipine (Group II)
Trial: 23849436
Drug: Fasting state
RxNorm normalized name: CLOZAPINE (GOLDEN STATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting state (clinofibrate 400 mg)
Trial: 23849436
Drug: Fed state
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fed state (clinofibrate 400 mg)
Trial: 21181364
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment plus simvastatin (group R+S)
Trial: 21181364
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (group R)
Trial: 17428528
Drug: Dexamphetamine (10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (10mg daily for 5 days)
Trial: 10343626
Drug: Inhaled Fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Fluticasone Propionate (FP)
Trial: 10343626
Drug: Inhaled Triamcinolone
RxNorm normalized name: triamcinolone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Triamcinolone Acetonide (TAA)
Trial: 10343626
Drug: Intranasal Fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Fluticasone Propionate (FP)
Trial: 8606898
Drug: Neurodevelopmental treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodevelopmental treatment (NDT) for 5 days
Trial: 8606898
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration (both types)
Trial: 1945978
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (chloral hydrate 50 mg/kg + hydroxyzine pamoate 25 mg + meperidine 1.5 mg/kg)
Trial: 7047580
Drug: Buprenorphine (0.3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.3, 0.45, or 0.6 mg)
Trial: 20137767
Drug: Tramadol Contramid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol Contramid OAD 200 mg tablets
Trial: 20137767
Drug: Monocrixo L.P.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocrixo L.P. 200 mg capsules
Trial: 8295245
Drug: Clotrimazole 10
RxNorm normalized name: clotrimazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole 10 mg three times a day
Trial: 14551182
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg per day
Trial: 3389331
Drug: Medium-chain triglycerides
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-chain triglycerides (MCT) at doses of 100, 200, and 300 kcal
Trial: 30572528
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl patch (TFP) 25 μg/h
Trial: 20954214
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of ondansetron (8 mg)
Trial: 9262266
Drug: Modified suppression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified suppression gonadotrophin-releasing hormone agonist protocol
Trial: 8486173
Drug: 4 or
RxNorm normalized name: Dex4 Orange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 or 8 mg of oral E2 and vaginal ultrasound (US) daily until endometrial thickness > or = 6 mm with a triple‐line pattern